|
Pathophysiology of Chemotherapy-Induced Cognitive Deficits in Juvenile Rats
|
5R01CA182284-04
|
$346,525
|
$346,525
|
COLE, PETER
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Markers of Cognitive Decline During Treatment for Childhood ALL
|
5R21CA187226-02
|
$215,938
|
$215,938
|
COLE, PETER
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Core Support for Cancer Center
|
3P30CA013330-44S1
|
$199,871
|
$7,995
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Core Support for Cancer Center
|
3P30CA013330-44S2
|
$199,989
|
$8,000
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Core Support for Cancer Center
|
3P30CA013330-44S3
|
$500,000
|
$20,000
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Core Support for Cancer Center
|
5P30CA013330-44
|
$3,746,138
|
$149,846
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Assay Development for NSD1 Methyltransferase Inhibitor Discovery
|
5R01CA191077-02
|
$312,244
|
$312,244
|
NAPPER, ANDREW
|
ALFRED I. DU PONT HOSP FOR CHILDREN
|
|
Identifying Cell Stress Proteins that Predict Clinical Response in Pediatric AML
|
4R01CA164024-04
|
$309,159
|
$309,159
|
HORTON, TERZAH
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-10S1
|
$118,016
|
$4,721
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-10S2
|
$170,897
|
$6,836
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-10S3
|
$118,875
|
$4,755
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-10S4
|
$499,947
|
$19,998
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-10S5
|
$134,220
|
$5,369
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-10
|
$3,253,119
|
$130,125
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Using Stat3 Signaling Profiles to Understand Chemotherapy Resistance in AML
|
5R01CA175026-03
|
$402,343
|
$402,343
|
REDELL, MICHELE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Pharmacological modulation of epigenetic changes in AML
|
5R01CA102031-11
|
$342,107
|
$171,054
|
MARCUCCI, GUIDO
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-33S1
|
$125,651
|
$1,257
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-33S2
|
$124,999
|
$1,250
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-33S3
|
$37,400
|
$374
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-33S4
|
$350,000
|
$3,500
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
4P30CA033572-33
|
$2,520,000
|
$25,200
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Development of Novel Therapeutic Strategies in Human Leukemias
|
5P01CA066996-18
|
$2,249,567
|
$269,948
|
EBERT, BENJAMIN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-26S1
|
$20,833
|
$208
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-26S2
|
$60,000
|
$600
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-26S3
|
$118,406
|
$1,184
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-26S4
|
$200,000
|
$2,000
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
4P30CA043703-26
|
$4,895,515
|
$48,955
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Cdk5 signaling in ICN1-induced T Cell Leukemogenesis
|
5R21CA181875-02
|
$172,369
|
$172,369
|
HUANG, ALEX
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Targeting B cell activating factor receptor (BAFF-R) as a novel therapeutic strategy for drug resistant Acute Lymphoblastic Leukemia (ALL)
|
1R21CA201775-01A1
|
$206,843
|
$206,843
|
PARAMESWARAN, RESHMI
|
CASE WESTERN RESERVE UNIVERSITY
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-03S1
|
$3,025,319
|
$1,013,482
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
5U10CA180886-03
|
$21,084,883
|
$7,063,436
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Molecular Interactions of APOBEC3 Enzymes with the Cancer Genome
|
1K08CA212299-01
|
$148,742
|
$148,742
|
GREEN, ABBY
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Bone Deficits and Excess Adiposity after Pediatric Bone Marrow Transplantation
|
4K07CA166177-04
|
$164,901
|
$164,901
|
MOSTOUFI-MOAB, SOGOL
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
PI3K Pathway Inhibition for Philadelphia-Like Acute Lymphoblastic Leukemia
|
5K08CA184418-03
|
$169,657
|
$169,657
|
TASIAN, SARAH
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Improving risk allocation and developing novel therapies for children with T-ALL
|
5R01CA193776-02
|
$626,176
|
$626,176
|
TEACHEY, DAVID
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Exploring the oncogenic potential of human APOBEC3 cytosine deaminases
|
5R21CA185799-02
|
$219,240
|
$74,542
|
WEITZMAN, MATTHEW
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Development of novel selective Rac inhibitors for refractory leukemias
|
1R01CA202756-01A1
|
$638,223
|
$638,223
|
WILLIAMS, DAVID
|
CHILDREN'S HOSPITAL CORPORATION
|
|
Training Physician Scientists in Pediatric Oncology
|
2T32CA009659-21A1
|
$64,768
|
$32,384
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Investigating the mechanism of ITGA4/6-mediated chemoprotection of ALL cells
|
4R01CA172896-04
|
$335,154
|
$335,154
|
KIM, YONG-MI
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Adipocytes are Important Players in the Acute Lymphoblastic Leukemia Microenvironment
|
1R01CA201444-01A1
|
$413,948
|
$413,948
|
MITTELMAN, STEVEN
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
KIR-FAVORABLE HAPLOIDENTICAL TRANSPLANTATION IN CHILDREN
|
7R01CA181050-03
|
$370,071
|
$370,071
|
PULSIPHER, MICHAEL
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Therapeutic Elimination of Stem Cells for Relapsed Pediatric AML
|
5U01CA183030-03
|
$472,123
|
$472,123
|
LIU, YANG
|
CHILDREN'S RESEARCH INSTITUTE
|
|
Nonadherence: Undermining health outcomes in pediatric HSCT?
|
4R01CA157460-05
|
$407,809
|
$203,905
|
PAI, AHNA
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
Therapeutic insights through patient derived leukemia xenografts
|
1R50CA211404-01
|
$172,232
|
$172,232
|
WUNDERLICH, MARK
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
Targeting non-classical oncogenes as therapy for T-ALL
|
4R01CA169162-05
|
$332,000
|
$166,000
|
DIACOVO, THOMAS
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-42S1
|
$120,000
|
$1,200
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-42S2
|
$60,000
|
$600
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-42S3
|
$121,873
|
$1,219
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-42S4
|
$150,866
|
$1,509
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-42S5
|
$199,541
|
$1,995
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
Total relevant funding to Childhood Leukemia for this search: $61,561,699
|